FDA Panel Recommends Covid Shot Update; Pfizer-China Deal; WHO Ebola Drug List

The Story

According to a statnews.com roundup, an FDA advisory panel recommended updating fall 2026 Covid shots to target the XFG variant (“stratus”). Separately, Pfizer and China’s Innovent Biologics agreed to a global cancer drug deal worth up to $10.5 billion. The World Health Organization identified three drugs that should be fast-tracked for the current Bundibugyo Ebola outbreak.

Key Facts

• FDA’s Vaccines and Related Biological Products Advisory Committee recommended updating fall Covid shots to target the XFG variant, a fast-growing strain nicknamed “stratus.”
• The meeting was the first since FDA Commissioner Marty Makary resigned; his resignation did not play a role.
• Makary drew criticism last year for imposing stricter requirements on who could get Covid shots.
• Pfizer and Innovent Biologics agreed to a global licensing and collaboration deal worth up to $10.5 billion for 12 early-stage cancer medicines.
• The deal includes a $650 million upfront payment and up to $9.85 billion in milestone payments.
• The partnership covers antibody-drug conjugates and multi-specific antibodies, with eight Innovent-originated assets and four Pfizer-proposed programs.
• The value of similar deals in the greater China region rose from 2021 to an unprecedented $137.7 billion last year.
• WHO identified maftivimab (Regeneron), MBP134 (Mapp Bio), and remdesivir (Gilead) for fast-track clinical testing for the Bundibugyo Ebola form.
• The Bundibugyo outbreak has infected more than 1,000 people in the Democratic Republic of the Congo, with cases also in Uganda.
• At last count, 10 confirmed deaths and 223 suspected deaths; the WHO said the outbreak could be much larger as the virus was thought to have circulated undetected.

Conflicting Reports

No conflicting reports identified in the source article.

Still Unclear

The full extent of the Bundibugyo Ebola outbreak, as the WHO stated it could be much larger due to undetected circulation.

Misconceptions

No widespread misconceptions addressed in the source article.

Key Figures

FDA Vaccines and Related Biological Products Advisory Committee; Marty Makary (former FDA Commissioner); Pfizer; Innovent Biologics; World Health Organization; Regeneron Pharmaceutical; Mapp Bio; Gilead Sciences

Sources: statnews.com